Malignant melanoma with monster cells showing massive cyclin D1 amplification.

The American Journal of dermatopathology (Impact Factor: 1.3). 07/2009; 31(4):402-3. DOI: 10.1097/DAD.0b013e31819f8316
Source: PubMed
1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are many possible indications and potential uses for molecular diagnostic techniques in the evaluation and management of melanocytic neoplasms. These include: (a) the identification of better diagnostic, staging, and prognostic markers; (b) the discovery of novel therapeutic targets; (c) the development of a molecular classification scheme, with the potential to stratify melanomas into subtypes which have similar pathogenesis, prognosis, and treatment responses; (d) the determination of patterns of genetic deletions and/or gains that are associated with different clinical outcomes in patients with metastatic melanoma; (e) an improvement in our ability to accurately classify melanocytic lesions that are currently considered morphologically ambiguous, such as atypical Spitz tumors; (f) the identification of individuals and populations at high-risk for melanoma development; and (g) the application of genetic testing to help identify candidates requiring more comprehensive clinical screening.
    03/2011: pages 73-103;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Markedly pleomorphic epithelioid cells with high mitotic activity, giant cell formation, very large atypical nuclei, multiple nucleoli and abundant cytoplasm characterize 'monster' cells and may indicate aggressive tumor behavior. Very rare reports of melanomas comprised of 'monster cells' or cells with comparable histomorphological features, found in tissue samples from skin, lymph nodes, CNS, oral cavity and ileum have been published in the literature. This case is the first such description in the lung, and it is characterized with a battery of immunohistochemical stains; BRAF mutation status was negative, and fluorescence in situ hybridization analysis revealed increased copy number gains in 11q (cyclin D1), which is associated with poor prognosis in melanoma. The presence of monster cells in melanoma was associated with aggressive behavior in the reported patient.
    Journal of Cutaneous Pathology 01/2013; 40(1):61-5. · 1.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context.-The 4-probe, multicolor, fluorescence in situ hybridization (FISH) panel targeting chromosomes 6 and 11 has shown promising sensitivity and specificity in distinguishing between benign nevi and malignant melanoma. Only a few studies have assessed the potential utility of FISH in classification of histologically ambiguous melanocytic lesions. In the United States, this assay is exclusively licensed to NeoGenomics Laboratories (Irvine, California), which provides the technical component and has developed an innovative service (MelanoSITE) allowing pathologists to interpret FISH results using a dedicated Web portal. Thus far, use of MelanoSITE as a diagnostic adjunct in the diagnosis of melanocytic lesions has not, to our knowledge, been reported in the literature. Objective.-To analyze 1.5 years of experience with the MelanoSITE melanoma FISH assay in the evaluation of histologically ambiguous lesions in the context of second opinion and routine dermatopathology practice. Design.-A prospective histologic/FISH correlation study of 140 cases. Results.-Twenty-seven percent of abnormal FISH results were false-positive results because of tetraploidy. After correcting for known false-positive results, all lesions considered atypical nevi showed normal FISH signals. Abnormal FISH signals were reported in 30% of lesions considered histologically borderline and in 48% of lesions in which a diagnosis of melanoma was favored. Conclusions.-Four-probe, multicolor FISH results for melanoma correlate with the microscopic assessments of histologically ambiguous lesions. Pathologists using MelanoSITE must be aware of the high rate of false-positive results from tetraploidy.
    Archives of pathology & laboratory medicine 04/2012; 136(12). · 2.88 Impact Factor